CTN-0082-A-1: COVID-19 Vaccine Readiness in People Who Use Substances in Community STI Clinics and Substance Use Intervention or Harm Reduction Programs in Eight Higher HIV Incidence Southeastern Cities
Susan Tross, PhD
Co-Lead Investigator
New York State Psychiatric Institute
st130@cumc.columbia.edu
Mary Hatch-Maillette, PhD
Co-Lead Investigator
Addictions, Drug & Alcohol Institute
University of Washington
hatchm@uw.edu
Research is needed to determine prospects for Covid-19 vaccine uptake among people living in higher prevalence communities, hit hard by serial surges, and enacting tenuous policies for COVID-19 mask use, social distancing, and business and social gathering restrictions. Such research is especially crucial for devising strategies to promote vaccine uptake among disenfranchised people of color, who are often limited by disparities due to lower resources and higher mistrust for adopting health care innovations. This research ought to include people with problem substance use, already living at higher risk due to its inherent life disruption and dysregulation, and heightened vulnerability to health conditions (e.g. HIV, hepatitis, etc.). The ongoing survey of PrEP and Opioid Use Related Services in STI Clinics presents a timely opportunity to study vaccine readiness in hard to reach and higher risk populations.
This ancillary study will administer a brief, one-time survey to participants completing the main survey. It aims to assess, 1) assess awareness of, willingness and intention to receive the Covid-19 vaccine; 2) barriers and facilitators to receiving the vaccine; 3) suggested venues for receiving the vaccine information; and 4) individual characteristics associated with willingness to receive the vaccine.
Related Studies
Related Resources
Node Involvement
Lead Node(s):
All Participating Nodes: